ID   Karpas-231
AC   CVCL_1822
SY   KARPAS-231; Karpas 231; KARPAS 231; KARPAS231; K231
DR   CLO; CLO_0037175
DR   EFO; EFO_0005389
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473540
DR   cancercelllines; CVCL_1822
DR   Cell_Model_Passport; SIDM01017
DR   Cosmic; 1281371
DR   Cosmic; 2297008
DR   Cosmic-CLP; 1327774
DR   DepMap; ACH-002255
DR   DSMZ; ACC-562
DR   DSMZCellDive; ACC-562
DR   ECACC; 06120601
DR   EGA; EGAS00001000978
DR   GDSC; 1327774
DR   GEO; GSM115820
DR   GEO; GSM1035318
DR   GEO; GSM1374586
DR   GEO; GSM1374587
DR   GEO; GSM1669974
DR   LINCS_LDP; LCL-1087
DR   PharmacoDB; KARPAS231_728_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1822
DR   Wikidata; Q54899491
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7849311;
RX   PubMed=8324225;
RX   PubMed=8574789;
RX   PubMed=8618432;
RX   PubMed=16960149;
RX   PubMed=26727417;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~30-40 hours (DSMZ=ACC-562); ~60 hours (ECACC=06120601).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 1001; BCL6 + HGNC; 9211; POU2AF1; Name(s)=POU2AF1-BCL6, BOB1-LAZ3 (PubMed=8574789; PubMed=8618432).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.09%; East Asian, South=0%; South Asian=0.51%; European, North=68.07%; European, South=30.33% (PubMed=30894373).
CC   Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia (ALL-L3).
CC   Discontinued: DSMZ; ACC-562; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,14
ST   D13S317: 8,12
ST   D16S539: 11,13
ST   D18S51: 15,17
ST   D19S433: 14,15
ST   D21S11: 27,31.2
ST   D2S1338: 18,23
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 8,9
ST   D8S1179: 10,12
ST   FGA: 20
ST   Penta D: 12,14
ST   Penta E: 7,14
ST   TH01: 8,9.3
ST   TPOX: 8,9
ST   vWA: 18
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
//
RX   PubMed=8324225; DOI=10.1182/blood.V82.1.231.bloodjournal821231;
RA   Nacheva E., Dyer M.J.S., Fischer P., Stranks G., Heward J.M.,
RA   Marcus R.E., Grace C., Karpas A.;
RT   "C-MYC translocations in de novo B-cell lineage acute leukemias with
RT   t(14;18) (cell lines Karpas 231 and 353).";
RL   Blood 82:231-240(1993).
//
RX   PubMed=8574789;
RA   Galiegue-Zouitina S., Quief S., Hildebrand M.-P., Denis C., Lecocq G.,
RA   Collyn-d'Hooghe M., Bastard C., Yuille M.A.R., Dyer M.J.S.,
RA   Kerckaert J.-P.;
RT   "Fusion of the LAZ3/BCL6 and BOB1/OBF1 genes by t(3;11) (q27;q23)
RT   chromosomal translocation.";
RL   C. R. Acad. Sci. III, Sci. Vie 318:1125-1131(1995).
//
RX   PubMed=8618432;
RA   Galiegue Zouitina S., Quief S., Hildebrand M.-P., Denis C., Lecocq G.,
RA   Collyn-d'Hooghe M., Bastard C., Yuille M.A.R., Dyer M.J.S.,
RA   Kerckaert J.-P.;
RT   "The B cell transcriptional coactivator BOB1/OBF1 gene fuses to the
RT   LAZ3/BCL6 gene by t(3;11)(q27;q23.1) chromosomal translocation in a B
RT   cell leukemia line (Karpas 231).";
RL   Leukemia 10:579-587(1996).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//